## PATENT ASSIGNMENT

# Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

### **CONVEYING PARTY DATA**

Name	Execution Date
Ugur Sahin	10/19/2010
Ozlem Tureci	10/13/2010
Michael Koslowski	10/28/2010

### **RECEIVING PARTY DATA**

Name:	Ganymed Pharmaceuticals AG, a German corporation	
Street Address:	Freiligrathstrasse 12	
City:	Mainz	
State/Country:	GERMANY	
Postal Code: 55131		

Name:	Johannes Gutenberg-Universitat Mainz	
Street Address:	et Address: Saarstrasse 21	
City:	Mainz	
State/Country:	GERMANY	
Postal Code:	55122	

### PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	12765251

### **CORRESPONDENCE DATA**

Fax Number: (312)775-8100

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Email: mhmpto@mcandrews-ip.com

Correspondent Name: McAndrews Held & Malloy, Ltd.

Address Line 1: 500 West Madison Street

Address Line 2: Suite 3400

Address Line 4: Chicago, ILLINOIS 60661

PATENT

REEL: 025366 FRAME: 0586

40.00 127652

501351445

ATTORNEY DOCKET NUMBER:	22939US01
NAME OF SUBMITTER:	Angeline R. Babel
Total Attachments: 3 source=22939US01_Exec_Assignment#page1.tif source=22939US01_Exec_Assignment#page2.tif source=22939US01_Exec_Assignment#page3.tif	

PATENT REEL: 025366 FRAME: 0587

#### PATENT ASSIGNMENT

WHEREAS, we, Ugur Sahin, Özlem Türeci and Michael Koslowski (collectively the "the Assignors") have made new and useful inventions and improvements disclosed in a United States patent application entitled "IDENTIFICATION OF TUMOR-ASSOCIATED MARKERS FOR DIAGNOSIS AND THERAPY" and identified as Case No. 22939US01 in the offices of McANDREWS, HELD & MALLOY, LTD., filed in the United States Patent and Trademark Office as Serial No. 12/765,251, which was a national-stage entry of International Patent Application Serial No. PCT/EP2008/008924, filed on October 22, 2008, and in any and all other (provisional or non-provisional) applications both United States and foreign based thereon that claim priority thereto, which the undersigned may file. either solely or jointly with others, on said invention or improvements, and in any and all Letters Patent of the United States and foreign countries, which may be obtained on any of said applications, and in any continuation, continuation-in-part, divisional, reexamination, renewal, substitutions, reissue or extension of such applications or patents, and further assigns to said assignee the priority right provided by the International Convention, treaties or otherwise.

WHEREAS, Ganymed Pharmaceuticals AG, a German corporation having a place of business at Freiligrathstrasse 12, Mainz, Germany 55131, together with Johannes Gutenberg-Universität Mainz, having a place of business at Saarstrasse 21, Mainz, Germany 55122, (collectively "the Assignees") is desirous of acquiring the title, rights, benefits, and privileges hereinafter recited.

NOW, THEREFORE, in exchange for good and valuable consideration in hand paid, the receipt, adequacy, and sufficiency of which are hereby acknowledged, the Assignors hereby assign to the Assignees, their successors and assigns, the entire right, title and interest in and to said application and the inventions and improvements disclosed therein, and in any and all other United States (provisional or non-provisional) applications based thereon or that claim priority thereto, including any continuation, continuation-in-part, divisional application that the Assignors may file, either solely or jointly with others, and in any and all Letters Patent of the United States that may be obtained on any of said applications, and in any reexamination, renewal, substitution, reissue or extension of such applications or patents, and every priority right that is or may be predicated upon or arise from said inventions, improvements, applications, and Letters Patent.

The Assignors hereby authorize the Assignees to file patent applications in any or all countries for any or all of said inventions and improvements in our name or in the names of the Assignees or otherwise as said Assignees may deem advisable, under the International Convention or otherwise. The Assignors hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent to said Assignees.

The Assignors warrant to be the owner of the entire right, title and interest in said invention or improvements and to have the right to make this Assignment, and

PATENT REEL: 025366 FRAME: 0588 further warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

The Assignors hereby agree, upon the request and at the expense of said Assignees, their successors and assigns, to execute any and all continuation, continuation-in-part, divisional, extension, renewal, and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination or extension of any Letters Patent that may be granted upon said application, that said Assignees, their successors or assigns may deem necessary or expedient; and to cooperate to the best of the ability of the Assignors with said Assignees, their successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain said Letters Patent in the United States, and vest all rights therein hereby conveyed in the Assignees, their successors and assigns, whereby said Letters Patent will be held and enjoyed by the said Assignees, their successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors if this Assignment had not been made.

By way of an Addendum to Patent Assignments, which was executed on May 19, 2010 and June 2, 2010, Ganymed Pharmaceuticals AG ("Ganymed") and Johannes Gutenberg-Universität Mainz ("Universität Mainz") have acknowledged that, as to the relationship between the Ganymed and Universität Mainz, the terms of this Assignment shall be subject to the terms of the Cooperation Treaties entered into between Universität Mainz and Ganymed dated June 28, 2005 and December 30, 2008, including, but not limited to, Articles 2.3.1 - 2.3.8 of the Treaty dated June 28, 2005 and Articles 2.3.1 - 2.3.9 of the Treaty dated December 30, 2008. In the event of any conflict or inconsistency between the terms of the Cooperation Treaties and the terms of this Assignment, the terms of the Cooperation Treaties shall supersede and govern.

This Assignment shall be binding upon and shall inure to the benefit of the Assignees and Assignors and their respective successors and assigns.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.

[SIGNATURE PAGES FOLLOW]

CASE No. 22939US01

EXECUTED this 15 day of 00, 2010.	O queda
	( Ugur Sahin
WITNESSED by A 10 mg/	this 19 day of OCT, 2010.
WITNESSED by	this <u>\lambda \lambda </u>
<b>EXECUTED</b> this $13$ day of $24$ , $2010$	
$\Lambda$	ferm
1 1	Özlem Türeci
WITNESSED by U	this <u>\</u> day of <u>OCT</u> , 20 <u>\0</u> .
WITNESSED by July	this <u>\\\ 3</u> day of <u>\( \CCC</u> , 20 <u>\( \O</u> .
<b>EXECUTED</b> this $28$ day of $000$ , $2010$ .	(Johon o)
/	Michael Koslowski
WITNESSED by	this <u>28</u> day of <u>OCI</u> , 20 <u>10</u>
WITNESSED by	this $28$ day of $0$ , 20 $0$